Team

Avatar placeholder

Dr Savvas Neophytou

Partner, Head of Life Sciences

Savvas is the Head of Life Sciences at Deepbridge. Prior to joining Deepridge, Savvas enjoyed a 15 year career in the City, working as an investment banker at JP Morgan, Bear Stearns, Shore Capital, Cantor Fitzgerald, and Panmure Gordon. Savvas was also CEO of telemedicine business Now Healthcare Group.  As a highly acclaimed analyst, Savvas has won multiple awards, most recently in 2015 when Savvas was ranked 2nd overall in the prestigious Reuters Starmine survey, a position he also held in 2014. In the same year, Savvas was also runner-up in the CityAM Analyst of the Year awards. Savvas holds a PhD in psychopharmacology from Nottingham University and a BSc (Hons) degree in pharmacology from Manchester University.


linkedin
Avatar placeholder

Ian Warwick

Managing Partner

A successful entrepreneur and CEO with more than two decades of leading private and public companies, Ian has successfully led the turnaround, re-capitalization and listing of several businesses, returning them to profit. He currently holds personal investments in a number of technology companies whose new products are in the proof of concept stage. He holds a Business Education Diploma from the University of Newcastle, and a Licentiateship (LCGI) (NVQ Level 4) from the Royal Navy.


linkedin
Avatar placeholder

Fuchsia Curry

Syndicate Manager

Fuchsia manages Deepbridge Syndicate, the online capital raising platform of Deepbridge Capital. With a degree in Financial and Business Economics from Newcastle University, prior to joining Deepbridge Fuchsia was Client Relationship and Business Development Manager at AngelNews, a leading venture capital focussed news service and national events company for private investors and the companies they invest in.  

With a wealth of experience in the venture capital sector, Fuchsia was also a co-founder and inaugural committee member of Greenshoots, the junior branch of the Enterprise Investment Scheme Association (EISA).


linkedin
Avatar placeholder

Prof. Chris Wood

Senior Medical Adviser

Over 20 years of experience in the biotechnology sector, Chris has founded, managed and successfully exited two biotechnology companies, Bioenvision Inc. (NASDAQ:BIV, which grew to a market capitalization of $345 million, and was acquired by Genzyme Corporation in October 2007), and Medirace Limited (later Medeva PLC, traded on both the London Stock Exchange and the New York Stock Exchange, and subsequently acquired by Celltech Group PLC, now UCB, for £554 million). An Honorary Professor at Imperial College London, Chris holds an M.D. from the University of Wales School of Medicine, and is a Fellow of the Royal College of Surgeons of Edinburgh.


linkedin
Avatar placeholder

Kieran O'Gorman

Technical Partner

With a wealth of experience in financial services, including institutional fund management within the Lloyd’s of London insurance community, and HNW private client stockbroking at Popes Stockbrokers (now Brewin Dolphin), Kieran has an indepth knowledge of the private capital markets, involving capital raising, investor relations and communication, and is responsible for the fund-raising activities at Deepbridge. Kieran has been a Fellow of the Chartered Institute of Securities and Investments since 2001.

Through his position on the Investment Supervisory Committee, Kieran acts as a conduit between the Executive Team at Deepbridge and the Independent Committee Team, thus ensuring the Independent Committee have access to all information required to assist them in making sound and strategic investment decisions on a timely basis.


linkedin
Avatar placeholder

Prof. Nagy Habib

Supervisory Investment Committee Member - Life Sciences

Nagy Habib is Professor of Hepatobiliary Surgery, at the Department of Cancer Surgery, at Imperial College London. With principal research activities focusing on the improvement of surgical technologies, Nagy has also been instrumental in the development of remediation and/or cure of diseases of the liver as either a complement or replacement to surgery with particular focus on gene therapy, the use of stem cells and immunotherapy. Nagy has also pioneered novel clinical trials for the treatment of liver cancer. Nagy has extensively published on a wide range of related topics, and is the inventor of, and co-author of the first publication about the use for, radiofrequency in devices used in liver surgery. Awarded by the Advisory Committee for Clinical Excellence, which is given in recognition of exceptional contributions from NHS consultants, Nagy has been named as one of Britain’s top surgeons by the Saturday Times Magazine in 2011.


linkedin
Avatar placeholder

Prof. Raj Chopra

Supervisory Investment Committee Member - Life Sciences

Professor Raj Chopra is Director of the Cancer Research UK Cancer Therapeutics Unit and Head of the Division of Cancer Therapeutics.  He is currently a member of the Cancer Research UK Drug Discovery Committee and of the Scientific Board of the California Institute of Regenerative Medicine (CIRM).  Raj received his M.D. at the University College and Middlesex School of Medicine, London and his Ph.D. from the University of London. Raj was previously part of the leadership team for the largest Oncology group in AstraZeneca, and established Translational Medicine for AstraZeneca in Boston, Massachusetts, US. He was also a leader within the Executive R&D Team and Corporate Vice President of Translational and Early Drug Development at Celgene Corporation.  In addition, he has been a Non-Executive Director for e-Therapeutics (Oxford, UK) and has been on the Board of Agios (Boston, Massachusetts, US).


linkedin
Avatar placeholder

Geoff Davison

Supervisory Investment Committee Member - Life Sciences

Geoff is the Chief Executive of Bionow, the life sciences membership organisation for the North of England. Having founded the business in 2011, Bionow has 15 University members and 300 industry members across the North of England and North Wales. Geoff is regularly invited to advise and comment on industry requirements and represent the Bionow membership both regionally and nationally. Previously, Geoff founded 2 biotech companies, Biorite Ltd and Advanced Biomedical Ltd, both spin-out companies from the University of Manchester focused on developing point of care diagnostic technologies. Geoff has a degree in Biochemistry and a PhD from the School of Pharmacy, University of Manchester where he began his career undertaking postdoctoral research in the area of enhanced payload responsive liposomal drug delivery systems.

Geoff is also a Board Member and Treasurer of the Academy of Pharmaceutical Sciences, a member of the Liverpool LEP Health and Life Sciences Advisory Board, member of Health Innovation Manchester Exec group and member of Northeast LEP Health and Life Sciences Advisory Board.


linkedin
Avatar placeholder

Dr Gary O'Hare

Supervisory Investment Committee Member - Life Sciences

Gary graduated from Trinity College, Dublin with MB BCh BAO, in 1997. Subsequently he undertook training in various medical specialities prior to being awarded AFRCSI from Royal College of Surgeons, Ireland in 2001. Subsequently he undertook general practice training in the Mersey Deanery and was awarded Merit in the MRCGP examinations 2006. Further he studied at Manchester University to obtain Certificate of Occupational Health. Gary has been a GP Principal and Partner in an 8000 patient practice in Cheshire. This experience gives him an understanding of front-line medical services and a distinct insight into the needs of patients and clinicians. Gary is also clinical lead for Primary Care, a Governing Body member at Halton CCG and has been selected to study on the Nye Bevan program at the NHS leadership Academy.


linkedin
Avatar placeholder

Lloyd Price

Supervisory Investment Committee Member - Life Sciences

Lloyd co-founded, launched and scaled Zesty from an idea in July 2012 into one of the UK’s leading Digital Health companies, winning multiple awards and raising in excess of $10M in funding.

Zesty was selected as “1 of the UK’s 30 Finest Early Stage Technology Businesses” by TechCityUK for the Upscale program in 2015 and subsequently Lloyd was voted “1 of the 100 most influential people in HealthTech globally” in 2016 by HotTopics magazine.

Prior to his 5 years in Healthcare, Lloyd had 15 years’ experience building Digital Businesses within 6 Industries - Retail, Travel, Finance, Advertising, Dating and Social Networking. Lloyd studied Business Administration at Coventry University and Corporate Finance at London Business School.


linkedin
Avatar placeholder

Miss Rebecca Roberts

Supervisory Investment Committee Member - Life Sciences

Rebecca is a paediatric surgeon at the Bristol Royal Hospital for Children.  A member of the Royal College of Surgeons (England) and the British Association of Paediatric Surgeons, she has experience in surgical and medical settings in India, Tanzania, South Africa and Cambodia.  Graduating from The University of Sheffield Medical School, Rebecca also holds a Masters’ in Health Research from the University of Lancaster and the Diploma in Tropical Medicine & Hygiene from the London School of Hygiene & Tropical Medicine. She is an Advanced Paediatric Life Support Instructor and has presented her research at many national and international surgical conferences.


linkedin
Avatar placeholder

Andrew Aldridge

Head of Marketing

As Head of Marketing, Andrew oversees all Deepbridge communications and messaging. Andrew has a wealth of experience marketing financial and professional institutions, with over a decade of experience building credible brands and delivering real growth.

Andrew is a Member of The Chartered Institute of Marketing and holds a BSc in Business Economics and Marketing from the University of Wales, Aberystwyth. Andrew is also a trustee of the Tim Parry Johnathan Ball Foundation For Peace.


linkedin